Blood Cancer Journal - Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.

Leukemia - The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms

Edited by Associate Editor Hervé Dombret, this How I Treat series highlights the clinical approach to high-risk subgroups of acute lymphoblastic leukemia (

Key PointsFLT3-ITD MRD identifies patients at high relapse risk after intensive chemotherapy with midostaurin.Conversion from FLT3-ITD MRDneg to FLT3-ITD M

Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge

Click on the article title to read more.

Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge

On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.